Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Ovarian Cancer


 CHAD                                                 ovarian(114)
 _________________________________________________________________
  cytoxan......... 600 mg/sqm IV day 1.
  hexamethylmelami 150 mg/sqm/day orally from day 8 to day 22.
  adriamycin...... 25 mg/sqm IV day 1.
  cisplatin....... 50 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 28 days.

  reference...
    Vogl SE.  Pagano M.  Kaplan BH.  Greenwald E.  Arseneau J. 
    Bennett B. Cis-platin based combination chemotherapy for 
    advanced ovarian cancer. High overall response rate with 
    curative potential only in women with small tumor burdens. 
    Cancer.  51(11):2024-30, 1983 Jun 1. 
  abstract...
    Thirty-eight women with advanced ovarian cancer were given 
    monthly cycles of intravenous cyclophosphamide, Adriamycin 
    (doxorubicin) and cis-platin, and oral hexamethylmelamine. Of 
    26 with tumor which would be evaluated for response, 42% had 
    complete remission and 50% partial remission. Median time to 
    disease progression from entry for all 38 patients was 13 
    months, and median survival 23.5 months. The bulk of tumor at 
    the time chemotherapy was begun was the only significant 
    prognostic factor for time to disease progression and 
    survival. Of the seven women surviving free of disease a 
    median of three years later, five had no mass greater than 2 
    centimeters in diameter at entry. Toxicity was predominantly 
    myelosuppression and vomiting, with mild peripheral neuropathy 
    in 27% and no significant renal or cardiac toxicity. The 
    response rate of 92% is much higher than that previously 
    reported with melphalan, and the survival considerably longer. 
    The toxicity is acceptable, given the substantial improvement 
    in results. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.